Search results for "harm"
showing 10 items of 13866 documents
Polyphenols and Pharmacological Screening of a Monarda fistulosa L. dry Extract Based on a Hydrodistilled Residue By-Product
2021
This study aimed to determine the composition and content of polyphenols in the dry extract obtained from the hydrodistilled residue by-product of the wild bergamot (Monarda fistulosa L., Lamiaceae Martinov family) herb (MFDE) and to evaluate its safety and pharmacological properties. The total phenolic content (TPC) in the MFDE was 120.64 mg GAE/g. The high-performance liquid chromatography (HPLC) analysis showed the presence of a plethora of phenolic compounds, including hydroxycinnamic acids and flavone derivatives in the MFDE, with rosmarinic acid and luteolin-7-O-glucoside being the main components. With an IC50 value of 0.285 mg/mL, it was found to be a strong DPPH radical scavenger. …
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial
2020
Funding: Transgène; International audience; Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort and pre-clinical studies have established the link between a functional T-cell-mounted immunity and resolution of infection. TG1050 is an adenovirus 5-based vaccine that expresses HBV polymerase and domains of core and surface antigen and has shown immunogenicity and antiviral effects in mice. We performed a phase 1 clinical trial to assess safety and explore immunogenicity and early efficacy of TG1050 in CHB patients. This randomized, double blind, placebo-controlled study included two sequential phases: one single dose cohort (SD, n = 12) and one …
Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients
2021
Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are chronic diseases associated with increased morbidity and reduced quality of life. Age may represent a risk factor for adverse events, due to the multimorbidity and polypharmacy, common in elderly patients. Elderly are often not included in clinical trials evaluating efficacy and safety of study drugs for the treatment of inflammatory bowel diseases. Several drugs, such as aminosalicylates, systemic corticosteroids, immunosuppressant drugs, biological drugs and Janus Kinase inhibitors, are available for the management of inflammatory bowel diseases. With the increasing spectrum of therapeutic options, it is th…
Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b vaccine; Infanrix™ hexa: T…
2014
Infant vaccination using 2-dose priming at 3 and 5 mo of age with a booster at 11–12 mo of age was pioneered in Italy. The 3-5-11 schedule is now used in a growing number of European countries. Infanrix™ hexa (DTPa-HBV-IPV/Hib, GlaxoSmithKline Vaccines) was first licensed for use in 2000 and has been the only pediatric hexavalent vaccine available since 2005. We reviewed available clinical trial data describing the immunogenicity of DTPa-HBV-IPV/Hib when administered at 3, 5, and 11 mo of age, and conducted an analysis of safety using global and Italian post-marketing surveillance data. In Italy, DTPa-HBV-IPV/Hib has a demonstrated safety record extending over a decade of use, it has been a…
Tenapanor for the treatment of irritable bowel syndrome with constipation.
2020
Introduction: Irritable bowel syndrome with constipation is associated with higher rates of functional impairment, as compared to other subtypes of the syndrome. Conventional laxative-based pharmacologic therapy of IBS-C, which is mostly symptom-based, is often unsatisfactory. Tenapanor represents a first-in-class orally available inhibitor of NHE3, which is minimally absorbed in the GI tract, what constitutes a significant therapeutic benefit, as it may act on the drug target. Areas covered: Aim of this article is to sum up the evidences about pharmacodynamics and pharmacokinetics of tenapanor, focusing on animal models and in vitro studies, but also discuss clinical trials on tenapanor's …
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multi…
2018
BACKGROUND: The aim of the study was to evaluate the achievement of 'no evidence of disease activity' (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment. METHODS: A time-to-event method was used to determine the percentages of patients with RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed disability progression, and no new T2/gadolinium-enhancing brain lesions). We described the safety profile of the investigated drugs. RESULTS: Of the 587 pwRRMS treated with DMF and the 316 pwRRMS tre…
Organisaation merkityksentäminen sairaalajohtoryhmäkokouksissa
2016
Kokouksia järjestetään kaikissa organisaatioissa ja yhteiskunnissa ja ne vievät valmisteluineen suuren osan erityisesti johtajien työajasta. Tästä huolimatta kokousten roolia osana organisaation prosesseja on tutkittu ja jäsennetty teoreettisesti verrattain vähän. Tämä tutkimus keskittyy sairaalajohtoryhmien kokousvuorovaikutuksessa tapahtuvaan sairaalaorganisaation merkityksentämiseen (sensemaking). Tutkimuksen tavoite on ymmärtää johtoryhmien kokousvuorovaikutuksessa tapahtuvan sairaalaorganisaation merkityksentämisen roolia osana kokouksia ja koko organisaation toimintaa. Aineistona on kymmenen videoitua kokousta kahdelta eri organisaatiotasolta. Aineiston analyysi perustui vuorovaikutus…
Vuorovaikutus sairaalajohtoryhmien kokouksissa
2018
Lectio praecursoria viestinnän väitöskirjaksi tarkoitetun tutkimuksen Vuorovaikutus sairaalajohtoryhmien kokouksissa tarkastustilaisuudessa Jyväskylän yliopistossa 27.10.2018. Vastaväittäjänä toimi vanhempi yliopistonlehtori, dosentti Pekka Pälli (Aalto yliopisto) ja kustoksena yliopistonlehtori, FT Leena Mikkola (Jyväskylän yliopisto). nonPeerReviewed
Sairaalatyöyhteisön hallinnollisessa vuorovaikutuksessa rakennetaan työn resursseja ja työn yhteisyyttä
2018
Lectio praecursoria viestinnän väitöskirjaksi tarkoitetun tutkimuksen Hallinnollinen vuorovaikutus sairaalatyöyhteisössä tarkastustilaisuudessa Jyväskylän yliopistossa 6.4.2018. Vastaväittäjänä toimi yliopistonlehtori, dosentti Tuula-Riitta Välikoski (Tampereen yliopisto) ja kustoksena yliopistonlehtori, FT Leena Mikkola (Jyväskylän yliopisto). nonPeerReviewed
LA IMPORTANCIA DEL DINERO EN LA ELECCIÓN LABORAL
2014
Resumen: El objetivo fundamental del presente articulo es identificar los factores motivadores del trabajo entre los futuros directivos y trabajadores y reflexionar desde un punto de vista tanto academico como profesional sobre la importancia del dinero como factor motivador. Para ello, hemos tomado a estudiantes universitarios, en su faceta de futuros trabajadores; se concluye que el dinero por si solo no motiva y que es necesario encontrar aquel grupo de factores que motivan a los trabajadores con el objetivo de conseguir el maximo rendimiento. Los resultados nos permiten concluir que no debemos motivar tan solo con el dinero o admitiendolo como principal elemento motivacional. Palabras c…